Here are four payer-related headlines in the last two weeks for ASCs to know. 1. Medical practices and hospitals saw claims denials increase and prior authorization denials decrease in 2024, according ...

The Cigna Group (NYSE:CI)’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Cigna has announced a deal to cap client copays on popular GLP-1 weight loss drugs by Eli Lilly and Novo Nordisk at $200 per ...

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

The problem was resolved Thursday, when lawmakers sent a $240 million supplemental budget to Governor Maura Healey, which she ...

Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans and their members to prescription savings, announces today its GLP-1 ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership ...

The popularity of GLP-1 drugs has insurance companies scrambling to satisfy consumer access while reining in exorbitant costs ...